Skip to content
Screener

Pacific Biosciences of California PACB Business Segments — Total Revenue

Similar metrics at other companies

Arlo Technologies logo
ARLOReportable Segment — Total Revenue
$155.94M+20.5%
DocuSign logo
DOCUReportable Segment — Total Revenue
$830.24M+8.7%
Guidewire Software logo
GWREReportable Segment — Total Revenue
$372.54M+26.9%
UiPath logo
PATHReportable Segment — Total Revenue
$418.38M+17.3%
NSA
NSAReportable Segment — Total Revenue
$185.4M-1.6%
Andersen Group logo
ANDGReportable Segment — Total Revenue
$240.75M+15.7%

Other financials

Income statement

See full
Revenue$39.0M-1.9%
Gross profit$12.6M-13.9%
Operating income-$44.6M+0.5%
Net income-$44.7M-6.7%
EPS (diluted)-$0.140.0%

Balance sheet

See full
Cash & equivalents$62.6M+10.5%
Total debt$61.8M+17.1%
Total equity-$33.2M-154%
Total assets$751.9M-8.9%

Cash flow

See full
Operating cash flow-$35.6M-21.1%
CapEx$1.6M+183%
Free cash flow-$37.1M-24.1%

Valuation

See full
Market cap$357.46M-5.6%
Enterprise value$356.64M-4.8%
P/S2.2×-0.2×

Profitability

See full
Gross margin36.4%+15.0pp
Operating margin-83.5%-37.4pp
Net margin-82.5%-35.5pp
FCF margin-77.5%-13.2pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio4.9×-2.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001299130-26-000122
(In thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total revenue$39,007$39,766$76,185$76,919
Less:
Cost of revenue26,36925,08250,70663,606
Research and development23,02222,52942,63051,582
Sales and marketing18,49219,51634,27039,592
General and administrative14,90116,65930,27636,751
Impairment charges15,000
Settlement charges15,400

Item 1. Financial Statements (unaudited):

FAQ

What is Pacific Biosciences of California's business segments — total revenue?
Pacific Biosciences of California (PACB) reported business segments — total revenue of $39.01M in Q2 2026.
How has Pacific Biosciences of California's business segments — total revenue changed year-over-year?
Pacific Biosciences of California's business segments — total revenue decreased by 1.9% year-over-year, from $39.77M to $39.01M.
What is the long-term trend for Pacific Biosciences of California's business segments — total revenue?
Over 3 years (2022 to 2025), Pacific Biosciences of California's business segments — total revenue has grown at a 7.6% compound annual growth rate (CAGR), from $128.3M to $160.01M.
What does business segments — total revenue mean?
This represents the total gross income generated by the company's primary business segment from the sale of sequencing platforms, consumables, and related services. It serves as the primary indicator of market demand and the successful commercial adoption of the company's genetic analysis technology.

Ask your AI about Pacific Biosciences of California's business segments — total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude